PF-Atlas › Clinical Trials › NCT02173145

Azithromycin in Idiopathic Pulmonary Fibrosis

azithromycin · Not specified

Registry ID
NCT02173145
Phase
Not specified
Status
Completed
Drug / intervention
azithromycin
Sponsor
Insel Gruppe AG, University Hospital Bern
Start
2014-08-19
Enrollment
27
Locations
4

About this trial

Idiopathic pulmonary fibrosis (IPF) is a devastating disease with no cure available. Patients suffer from respiratory symptoms including dyspnea and cough. To improve life quality the investigators will test the effects of immunomodulation of macrolides specifically on cough in IPF patients. The investigators hypothesize that immunomodulatory treatment reduces cough frequency and might improve lung function.

View NCT02173145 on ClinicalTrials.gov →

Explore related

All azithromycin trialsAll IPF trials

Related trials

Azithromycin — NCT01270074Azithromycin — NCT05842681Azithromycin — NCT02960503Azithromycin — NCT02003911Azithromycin — NCT02803944
Medical disclaimer. This page summarizes public trial data for NCT02173145 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.